Diabetic Retinopathy Screening Point-of-Care Artificial Intelligence

NAEnrolling by invitationINTERVENTIONAL
Enrollment

848

Participants

Timeline

Start Date

July 27, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

January 31, 2026

Conditions
Diabetic Retinopathy (DR)
Interventions
DIAGNOSTIC_TEST

Diabetic Retinopathy screening Point of Care Artificial Intelligence

Random assignment of participants to intervention and control groups minimizes confounding variables. This ensures that any observed differences in outcomes are likely due to the intervention itself and not pre-existing differences between the groups. Participants of the DRES-POCAI study will be randomized into two groups: usual care (receive a retinal screening by an optometrist) or intervention group (receive a retinal screening using a special camera and EyeArt® system, an autonomous AI-based DR screening). The randomization will occur after consenting and completing the surveys, prior to conducting the DR screening process (for those randomized to the intervention group).

Trial Locations (2)

91910

San Ysidro Health Chula Vista, Chula Vista

92114

San Ysidro Health King-Chavez Health Center, San Diego

All Listed Sponsors
collaborator

Eyenuk, Inc.

INDUSTRY

collaborator

University of California, San Diego

OTHER

lead

Centro De Salud La Comunidad De San Ysidro Inc DBA: San Ysidro Health

OTHER